ITEMS IN AFP WITH KEYWORD:
May 15, 2021 Issue
Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List [Practice Guidelines]
The Pediatric Pharmacy Association produced a list of key potentially inappropriate drugs in pediatrics, or the KIDs List, to guide physicians who treat children.
What effect do sodium-glucose cotransporter-2 (SGLT2) inhibitors have on mortality and cardiovascular and renal outcomes in patients with and without diabetes mellitus, heart failure, or kidney disease?
Topical corticosteroids are an essential tool for treating inflammatory skin conditions. These medications are classified by strength and the risk of adverse effects. The quantity prescribed depends on the duration of treatment, the frequency of application, the skin location, and the total surface area treated.
The American Association of Clinical Endocrinologists and the American College of Endocrinology developed a summary of known risks of using off-label hormone treatments.
Oct 1, 2020 Issue
Alcohol Use Disorder: Pharmacologic Treatment Options [FPIN's Clinical Inquiries]
Acamprosate and naltrexone should be used as first-line agents for treatment of alcohol use disorder and are effective for reducing relapse rates. Agent selection should be based on comorbid conditions and adherence to the dosing regimen.
Vaginal, oral, and sublingual misoprostol in single doses of 600 to 800 mcg are equally effective for promoting completed abortion in patients with an incomplete first-trimester spontaneous abortion.
Acetaminophen is no better than placebo for relief of hip or knee pain due to osteoarthritis. Although acetaminophen does provide some pain relief, the effect is small and not clinically significant.
Higher doses of ibuprofen for acute pain relief offer no more benefit at 60 minutes than a single 400-mg dose. The same has been shown for chronic treatment of osteoarthritis. A higher, anti-inflammatory dose is not needed.
May 1, 2020 Issue
Megestrol for Palliative Care in Patients with Cancer [FPIN's Clinical Inquiries]
Megestrol may be considered as a component of palliative care nutritional support in patients with cancer.
The available evidence that treatment-resistant depression (depression that is unresponsive to two different treatments of adequate dose and length) responds well to augmentation treatment (i.e., adding psychotherapy, lithium, or aripiprazole [Abilify] to current treatment) is weak.